Spots Global Cancer Trial Database for Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
Official Title: Phase II Study of Nivolumab (Group 1) and Nivolumab Plus Relatlimab (Group 2) in Patients With Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin
Study ID: NCT04204837
Conditions
Study Description
Brief Summary: To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie, Graz, , Austria
LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie, Innsbruck, , Austria
Klinikum Klagenfurt am Wörthersee, Klagenfurt, , Austria
Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg, Salzburg, , Austria
Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, St.Pölten, , Austria
Med Uni Wien, Univ. Klinik für Dermatologie, Vienna, , Austria
Klinikum Wels-Grieskirchen GmbH, Wels, , Austria
Contact Details
Name: Martin Laimer, MD
Affiliation: Salzburger Landeskliniken
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
